{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-027349","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.298909+00:00","generated_at":"2026-05-26T21:37:17.835575+00:00","sec_items":["1.01","1.03","2.03"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Omega Therapeutics files for Chapter 11 bankruptcy with $9.8M DIP financing","bullets":["Filed voluntary Chapter 11 petition on February 10, 2025 in Delaware Bankruptcy Court.","Received interim approval for $9,820,908 DIP facility from Flagship affiliate; $3,931,953 funded Feb 13.","DIP includes roll-up of $1,475,178 prepetition note plus $165,000 fees; 10% interest, matures 70 days post-petition.","Court-approved milestones: final DIP order by day 30; asset sale order by day 60; closing by day 70.","Company remains debtor-in-possession; Flagship entities are significant stockholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-027349","json":"https://secwatch.observer/filing/0001193125-25-027349.json","markdown":"https://secwatch.observer/filing/0001193125-25-027349.md","text":"https://secwatch.observer/filing/0001193125-25-027349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525027349/0001193125-25-027349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525027349/d896578d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:37:17.835575+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"18ffc49462cef03049b05360080de3cc84a40e1d","claim":"Omega Therapeutics, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2025-02-10).","evidence_excerpt":"On February 10, 2025 (the “Petition Date”), Omega Therapeutics, Inc. (the “Company” or “Debtor”) commenced a chapter 11 case (the “Chapter 11 Case”) as debtor in possession in a voluntary proceeding under Chapter 11 of the United States Code","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000119312525027349/0001193125-25-027349-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the District of Delaware"},{"label":"Petition","value":"2025-02-10"}],"fact_type":"distress_event"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}